# A Repeat Dose Positron Emission Tomography Study With GSK1144814

> **NCT01209039** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 41 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** GSK1144814
- **DRUG:** GSK1144814
- **DRUG:** GSK1144814

## Key facts

- **NCT ID:** NCT01209039
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-01
- **Primary completion:** 2009-10-25
- **Final completion:** 2009-10-25
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01209039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01209039, "A Repeat Dose Positron Emission Tomography Study With GSK1144814". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT01209039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*